Furthermore, it is tempting to speculate that these TPα/TPβ-mediated effects may account, at least in part, for the clinically well-documented observation that during prostate cancer progression, AR-target gene expression is up-regulated even in the absence of testicular androgens or in the presence of AR antagonists, such as in the case of CRPC. This evidence concerns the gene AR and prostate carcinoma.